A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesaemia.

gan Vokes, E. E., Mick, R., Vogelzang, N. J., Geiser, R., Douglas, F.
Cyhoeddwyd 1990

Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study

gan Nilsson, S., Cislo, P., Sartor, O., Vogelzang, N. J., Coleman, R. E., O'Sullivan, J. M., Reuning-Scherer, J., Shan, M., Zhan, L., Parker, C.
Cyhoeddwyd yn Ann Oncol (2016)

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223

gan Sartor, O., Coleman, R. E., Nilsson, S., Heinrich, D., Helle, S. I., O’Sullivan, J. M., Vogelzang, N. J., Bruland, Ø., Kobina, S., Wilhelm, S., Xu, L., Shan, M., Kattan, M. W., Parker, C.
Cyhoeddwyd yn Ann Oncol (2017)

Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analys...

gan Scosyrev, E., Ely, B.W., Messing, E.M., Speights, V.O., Grossman, H. B., Wood, D.P., de Vere White, R.W., Vogelzang, N.J., Trump, D.L., Natale, R.B., Tangen, C., Crawford, E.D., Thompson, I.M.
Cyhoeddwyd 2010

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

gan Chi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., Azad, A. A., Eigl, B. J., Heng, D. Y. C., Joshua, A. M., de Bono, J. S., Scher, H. I.
Cyhoeddwyd yn Ann Oncol (2016)

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

gan Grivas, P., Loriot, Y., Morales-Barrera, R., Teo, M. Y., Zakharia, Y., Feyerabend, S., Vogelzang, N. J., Grande, E., Adra, N., Alva, A., Necchi, A., Rodriguez-Vida, A., Gupta, S., Josephs, D. H., Srinivas, S., Wride, K., Thomas, D., Simmons, A., Loehr, A., Dusek, R. L., Nepert, D., Chowdhury, S.
Cyhoeddwyd yn BMC Cancer (2021)

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

gan Fradet, Y, Bellmunt, J, Vaughn, D J, Lee, J L, Fong, L, Vogelzang, N J, Climent, M A, Petrylak, D P, Choueiri, T K, Necchi, A, Gerritsen, W, Gurney, H, Quinn, D I, Culine, S, Sternberg, C N, Nam, K, Frenkl, T L, Perini, R F, de Wit, R, Bajorin, D F
Cyhoeddwyd yn Ann Oncol (2019)

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

gan Bellmunt, J., de Wit, R., Vaughn, D.J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N.J., Climent, M.A., Petrylak, D.P., Choueiri, T.K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D.I., Culine, S., Sternberg, C.N., Mai, Y., Poehlein, C.H., Perini, R.F., Bajorin, D.F.
Cyhoeddwyd yn N Engl J Med (2017)